Aclarion, Inc. has released a new video featuring Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic, discussing his clinical experience with the Nociscan diagnostic tool. The video highlights the growing integration of this technology into routine practice at one of the United Kingdom's leading private hospitals, with nearly 100 Nociscans conducted to date indicating sustained physician engagement. This adoption matters because it represents progress in addressing chronic low back pain, which affects approximately 266 million people globally, creating substantial healthcare burdens and treatment challenges.
Nociscan is a non-invasive solution that helps physicians differentiate between painful and non-painful discs in the lumbar spine by leveraging MR spectroscopy and proprietary signal processing to identify chemical biomarkers associated with disc pain. Mr. Sutcliffe, who also serves as Lead Clinician at The London Spine Clinic, noted that the technology provides valuable additional insight that complements traditional imaging. The clinical significance of this adoption is substantial because when used alongside other diagnostic tools, clinical data has demonstrated up to a 97% surgical success rate when all Nociscan-positive discs are treated.
Brent Ness, Chief Executive Officer of Aclarion, emphasized the importance of this milestone, stating that approaching 100 scans at a leading international center like The London Clinic is an important indicator of increasing adoption. This matters because it reinforces the potential for Nociscan to become a valuable tool in the evaluation of chronic low back pain, providing physicians with more objective data to guide treatment decisions. The technology represents an advancement in addressing a significant healthcare challenge by moving beyond traditional imaging methods that sometimes fail to identify the precise source of pain.
The continued utilization at The London Clinic suggests that Nociscan is gaining acceptance as a complementary diagnostic tool in spinal care. This development is important because it could lead to more precise identification of pain sources, potentially improving outcomes for patients suffering from chronic low back pain through better-targeted treatments. For physicians interested in learning more about the evidence-supported platform, additional information is available at https://www.aclarion.com. The growing clinical experience with Nociscan at prestigious medical institutions indicates a shift toward more objective, biomarker-based approaches in spinal diagnostics that could transform how chronic back pain is evaluated and managed.
